Oncology Venture’s DRP shows positive data to treat colorectal cancer
Category: #health  By Pankaj Singh  Date: 2019-09-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncology Venture’s DRP shows positive data to treat colorectal cancer

Colorectal cancer, also known as colon cancer, rectal cancer or bowel cancer, affects a patient’s rectum and colon. Reportedly, it is the third most common type of cancer detected in both women and men in the U.S.

In an attempt to minimize its privilege, Oncology Venture A/S, a Danish pharmaceutical company that has various cancer treatment therapy in trials, has recently revealed plans to display data on the ability of DRP® (drug response predictor) technology to forecast response to 5-FU anti-cancer treatment in last stage colorectal cancer at the annual congress of ESMO (European Society for Medical Oncology) held in Barcelona.

According to reliable sources, the company is creating its world-class DRP® technology by using AI proprietary algorithms. The DRP® platform could effectively be used to predict which patients would profit from 5-FU (Fluorouracil) after going through a surgery in the adjuvant setting.

The recent studies revealed that DRP® can successfully be used in late-stage, metastasized colorectal cancer patients, by utilizing the biopsy material acquired from the initial diagnosis.

Moreover, the company recently witnessed a change in its management when it announced the appointment of Steve Carchedi as its new CEO, along with its proposal to offer a rights issue of SEK 100 million. 

Sources cite that the earnings from this fundraising will be used in the commercialization of a specific number of clinical assets, thus refocusing the company towards commercial outlook.

Furthermore, the firm’s Board of Directors have agreed on a consensus to choose Carchedi as the new CEO of Oncology Venture, succeeding Dr. Peter Buhl Jensen, who will now take on the role of the Chairman in the company’s Medical & Scientific Advisory Board.

In addition to this, the firm’s Board of Directors have also proposed rights issue of SEK 100 million to offer financial resources that allow the latest management team to build and deliver against an operating plan and reworked budget coherent to the new commercial goals.

Source Credit: https://oncologyventure.com/press-release/oncology-venture-presents-positive-data-at-esmo-on-drp-as-a-response-predictor-for-5-fu-treatment-in-colorectal-cancer/#

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
By Pankaj Singh

Japanese automotive giant, Toyota has reportedly tapped Japanese oil & energy corporation, ENEOS, to explore the field of hydrogen-based power to help with the development of a hydrogen fuel-cell system that would power Woven City, Japan’s ...

KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
By Pankaj Singh

Gujarats leading solar power generating company, KPI Global, has recently announced receiving an order for building a 12.5 megawatts solar project under the captive power producer capacity from Surat-headquartered Anupam Rasayan India. It has been r...

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...